Drug Trial Radar · NCT01589445
Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects
Last checked: Nov 19, 2026Latest source record: Feb 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
Nov 2008
Primary completion
Dec 2009
Study completion Jun 2010
Sponsor
- Lead sponsor
- University of DhakaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders; University of Dundee
- First posted
- May 2, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
* The present study was undertaken to assess the efficacy and safety of two different insulin sensitizers (namely Pioglitazone and Metformin) among subjects with type 2 diabetes mellitus (T2DM) in Bangladesh. * A prospective, double-blind, single group, 'within-subject' designed clinical trial of 77 diagnosed T2DM patients out of 130 patients with glycosylated haemoglobin (HbA1c) ≥7.2±1.5%, aged 46±6.4 years and registered for diabetes treatment in Bangladesh Institute of Research and Rehabilitation in Diabetes Endocrine and Metabolic Disorders (BIRDEM) was carried out. * The study was conducted between November 2008 and September 2010. * Baseline data, included case history of the patients,anthropometric measurement, biomedical parameters psychosocial factors, were collected from each subject and then enrolled to receive treatment with 001 drug once daily for three months, then the patients were left for wash out with metformin 850mg once daily for one month; then they received 002 drug once daily for further three months. * Dietary chart was remained as before. * DNA was isolated by Chelex method using the primers and control DNA,restriction Digestion Enzyme Endonuclease Hae 111 for genotyping PPARγ-(Peroxisome Proliferator Activated Receptor gamma)Pro12Pro * (Proline12Proline)/Pro12Ala-(Proline12 Alanine))/Ala12Ala-(Alanine12Alanine). * The blinded drugs were decoded after analyzing results, 001 tablet was pioglitazone (30 mg once daily) and 002 tablets was metformin (850mg once daily). Bio-medical outcomes were measured to assess the efficacy of both the drugs each month. After finishing the treatment period the effects of two drugs were compared using SPSS.And the association between the pioglitazone drug effects and genetic polymorphism was also assessed. * The metformin effects was assessed also using the response rate of HbA1c \<7.0% after 3 months treatment to the patients.
Conditions
- Type 2 Diabetes Mellitus
Interventions
Pioglitazone hydrochlorideDrug
77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
Metformin hydrochlorideDrug
After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of Changes in Fasting Serum Glucose (FSG)With Pioglitazone and MetforminTime frame: 3 months for each drug
- Comparison of Changes in Glycosylated Hemoglobin (HbA1c)With Pioglitazone and MetforminTime frame: 3 months for each drug
- Comparison of Changes in Insulin Levels (HOMA IR,QUICKI) With Pioglitazone and MetforminTime frame: 3 months for each drug
- Comparison of Changes in HOMA Percent B and HOMA Percent S With Pioglitazone and MetforminTime frame: 3 months for each drug
- Comparison of Changes in Fasting Serum Insulin (FSI)With Pioglitazone and MetforminTime frame: 3 months for each drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM)
Dhaka, Dhaka Division, Bangladesh
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.